A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver
M
Mark Tann, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
N/A
2 Locations
Brief description of study
The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage.
Detailed description of study
The purpose of this study is to look at the safety of radioembolization therapy with Yttrium 90 for liver disease.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: liver disease,HCC,liver cancer,hepatocellular carcinoma
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Subjects must have a diagnosis of hepatocellular carcinoma (HCC) and a treatment plan to undergo radioembolization therapy with Y-90 at Indiana University Health Hospital.
- Subjects must be willing and able to comply with all procedures and visits required for this protocol (pre-treatment, during treatment, and post-treatment).
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:
Participants will not be paid for their participation.
Updated on
25 Mar 2025.
Study ID: RADY-BTG-TANN-HIDA/0603, 1606072855
